Skip to main content

Teplizumab to delay type 1 diabetes onset

The primary findings of this TrialNet-based study of teplizumab showed that a 14-day course of the anti-CD3 monoclonal antibody significantly delayed onset of type 1 diabetes in high-risk people with two or more autoantibodies.

Receive weekly updates on the diabetes news that matters to you

The researchers hope to report new mechanistic and metabolic data at the 55th EASD Annual Meeting (EASD 2019):

Results from the Anti-CD3 mAb (teplizumab) prevention trial
Tuesday, September 17, 13:15–14:15. Vilanova Hall, Fira Barcelona Gran Via, Spain 
Session Chair: L. Chatenoud, France

  1. Clinical data, background, results, features of the participants associated with clinical responses; conclusions and significance. K. C. Herold, USA
  2. Studies of the mechanism of teplizumab. P. S. Linsley, USA
  3. Commentary. A. G Ziegler, Germany 

What our Editorial Board said:

A potentially interesting look at long-term data from trials of this potential immunotherapy for type 1 diabetes.

John Wilding, Professor of Medicine, UK

Back to the EASD 2019 conference hub